US pharma giant Merck & Co (NYSE: MRK) closed 1% higher on Thursday.
The company had earlier announced results from a Phase III trial alongside the European Organization for Research and Treatment of Cancer and the European Thoracic Oncology Platform.
"The sixth positive pivotal study evaluating a Keytruda-based regimen in earlier stages of cancer"It was found that adjuvant treatment with Keytruda (pembrolizumab) significantly improved disease-free survival (DFS), one of the study’s dual primary endpoints, reducing the risk of disease recurrence or death by 24% compared to placebo in stage IB to IIIA non-small cell lung cancer (NSCLC) following surgical resection, regardless of PD-L1 expression.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze